OncoMatch/Clinical Trials/NCT06877299
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
Is NCT06877299 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT) for lung cancer.
Treatment: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT) — This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Patients with known EGFR-sensitive mutations ... [are excluded]
Required: ALK fusion
Patients with known ... ALK fusion [are excluded]
Required: PD-L1 (CD274) expression testing required (testing required; no eligibility threshold specified)
tumor tissue or cell wax blocks that meet quality control standards for PD-L1 expression testing
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB
Demographics
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T cell receptors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06877299 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK fusion is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression testing required is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify